StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners cut their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a buy rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Trading Down 6.0 %

NASDAQ AWH opened at $0.75 on Tuesday. The company has a market cap of $9.36 million, a P/E ratio of -0.52 and a beta of 1.47. The company has a fifty day simple moving average of $0.95 and a 200 day simple moving average of $1.84. Aspira Women’s Health has a 12-month low of $0.74 and a 12-month high of $6.01.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the business earned ($0.28) EPS. Sell-side analysts predict that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.